After my multiple myeloma diagnosis two years ago, I started my bi-weekly chemotherapy regimen.  I quickly developed a routine.

Tuesdays and Fridays, I would take a ten-minute subway ride from our home in lower Manhattan to Greenwich Village, spend an hour at the clinic getting my “infusion,” and then stop off at one of the many great food stores at the cavernous Chelsea Market, a block from the clinic.

I’d then hop back on the subway and get to work, …

Earlier this week, the U.S. Food and Drug Administration approved subcutaneous administration of Velcade (see related Beacon news).  Previously, intravenous administration was the only approved method.

More details are provided in this article to answer multiple myeloma patients’ questions about the FDA decision.

What exactly did the FDA approve?

The FDA approved a supplemental new drug application for Velcade (bortezomib), which is an application to make changes to an already approved product.  Specifically, the FDA approved updated prescribing …

The Chinese New Year arrives this week. A culture with so much impact on the world can hardly be ignored. “The Year of the Dragon” suggests an energetic shift on the planet. The protective and powerful dragon symbolizes wisdom and prosperity. Generous, benevolent, and lucky, the dragon can transform into any type of creature and overcome all challenges.

Taming and transforming the multiple myeloma beast takes more than a dragon, but inspiration helps. Sometimes the dreams that occur during sleep …

Millennium: The Takeda Oncology Company announced today that the U.S Food and Drug Administration has approved subcutaneous administration of Velcade for the treatment of multiple myeloma and relapsed mantle cell lymphoma.

Velcade (bortezomib), which is marketed by Millennium and its parent company Takeda Pharmaceutical Company Limited (TSE:4502), is currently approved to be administered intravenously (infused into a vein).

The FDA decision to approve the subcutaneous administration of Velcade (injection into fat just below the skin, often abbreviated as subcu or …

Combined data from two recent Phase 1 clinical trials suggest that twice-weekly marizomib, with or without low-dose dexamethasone, may be effective for patients with relapsed or refractory multiple myeloma.

Dr. David Vesole from the John Theurer Cancer Center in Hackensack, New Jersey, who was not involved in the study, described marizomib as having “modest activity in relapsed/refractory myeloma.”

Dr. Paul Richardson from the Dana-Farber Cancer Institute in Boston presented the results at the American Society of Hematology (ASH) annual meeting …

Throughout 2011, The Myeloma Beacon published many articles that serve as helpful resources for multiple myeloma patients and others interested in myeloma.

These articles included interviews with, columns written by, and summaries of treatment guidelines from leading myeloma experts.  They also included articles providing helpful information about rare types of myeloma and exciting new treatment options that are being studied in clinical trials.

All these articles were published in addition to the Beacon's coverage of the latest myeloma-related news and …

How do you keep yourself from constantly thinking about this disease?

I realize I'm very fortunate to be healthy (except for the fact I have cancer) and don't have any of the physical issues associated with multiple myeloma that so many others have to deal with.  Consequently, however, the battle for me tends to be mostly psychological.

For me, that's not necessarily a good thing.

I have degrees in electrical engineering and mathematics, and as you might imagine, I'm a …